Metformin protects rotenone-induced dopaminergic neurodegeneration by reducing lipid peroxidation

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Metformin, a common antidiabetic medication, shows potential neuroprotective properties against neurotoxins.
• Previous studies suggest metformin's efficacy in mitigating 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity.
• This research explores metformin's protective effects against rotenone-induced dopaminergic neuron damage.

Purpose of the Study:

• To investigate the neuroprotective potential of metformin against rotenone-induced dopaminergic neuron damage.
• To elucidate the underlying mechanisms of metformin's neuroprotection in this model.

Main Methods:

• C57BL/6 mice were administered rotenone (2.5 mg/kg/day) for 10 days to induce dopaminergic toxicity.
• Metformin (300 mg/kg/day) was co-administered with rotenone for 10 days.
• Neuroprotection was assessed via tyrosine hydroxylase (TH), cleaved caspase-3, and α-synuclein immunohistochemistry in the substantia nigra (SN).
• Lipid peroxidation markers, malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), were quantified in SN tissues.

Main Results:

• Metformin treatment significantly attenuated the loss of TH+ neurons in the substantia nigra induced by rotenone.
• Metformin reduced elevated levels of cleaved caspase-3 and α-synuclein in the SN.
• A significant reduction in MDA and 4-HNE levels was observed in mice treated with both rotenone and metformin.
• No significant differences in motor behaviors were detected between experimental groups.

Conclusions:

• Metformin demonstrates neuroprotective effects against rotenone-induced dopaminergic neuron loss in the substantia nigra.
• The protective mechanism involves the reduction of lipid peroxidation.
• Metformin's ability to mitigate rotenone toxicity highlights its potential therapeutic role in neurodegenerative conditions affecting dopaminergic pathways.